Please login to the form below

Not currently logged in
Email:
Password:

Huntington's disease

This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.

EMA hands UniQure orphan status first in Huntington's

EMA hands UniQure orphan status first in Huntington's

Its Huntington’s disease candidate, currently known as AMT-130, becomes the first investigational AAV-gene therapy in this disease area to receive the status. ... UniQure ’s candidate fit the bill, not least because there are no currently approved

Latest news

More from news
Approximately 4 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... disease late last year, Bayer announced another gene editing pact this month with ERS Genomics.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease. ... Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    480. Isis Pharmaceuticals/ Roche. Collaboration. To develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.

  • Pharma deals during April 2013 Pharma deals during April 2013

    These deals, along with that announced with Moderna Therapeutics (messenger RNA therapies) and the purchase of AlphaCore (phase I programme for cardiovascular disease) earlier in the year exemplify AZ's focus ... Isis/ Roche. Isis, another biotech with a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. “ ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • VCCP Health

    Not only do they bring experience working on Rx accounts such as the immunology biosimilar portfolio for Novartis, but passion and expertise for animal health, disease awareness and charity work. ... 2016, Echoes of the past, Huntington's Disease (Teva).

  • Use of biomarkers in marketing

    pathway. When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’ s disease and Alzheimer’ s; these are prognosis biomarkers. ... A crowded market of biologics treating a chronic disease with very similar

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics